Search PubMed⌕ Search

Biomedical subjects

C M McKay

Publications and source records attributed to C M McKay.

26 records · Page 2Linked to original sources

Pitch ranking with nonsimultaneous dual-electrode electrical stimulation of the cochlea.

It has already been established that simultaneous activation of two intracochlear electrodes can evoke a pitch percept which is intermediate to that of either electrode when activated by itself. In the present study, this result has been extended to nonsimultaneous activation of nearby electrodes. Pitch perception was investigated for electric stimuli presented on one or two intracochlear electrode pairs. All stimuli were pulse trains of period 4 ms. In the dual-electrode stimuli, each period contained two biphasic pulses, separated by 0.4 ms, with one pulse for each electrode pair. These stimuli were compared with loudness-balanced single-electrode stimuli, having one pulse per period, generated on the same electrode pairs. Their pitches were ranked in a two-alternative forced-choice procedure by five experienced users of the 22-electrode implant manufactured by Cochlear Pty Limited. The studies showed that the pitch of a dual-electrode stimulus was intermediate to, and moved monotonically between, those of the component electrode pairs as the relative currents were altered in an orderly fashion. Intermediate pitches were achieved in all subjects at a range of cochlear positions, for electrode separations generally up to 3 mm. In half the cases a significantly different intermediate pitch could be created between adjacent electrodes. Further studies are necessary to establish whether intermediate pitches can be obtained at larger separations, as for simultaneous stimulation, and how they are affected by other factors such as the time between pulses or the spatial extent of the stimulation.

Cochlea↗

Pitch percepts associated with amplitude-modulated current pulse trains in cochlear implantees.

The percepts elicited by electrical stimulation of auditory neurons by trains of amplitude-modulated current pulses were studied in a group of six cochlear implant users. Modulation frequencies of 100, 150, and 200 Hz were studied, with a range of carrier rates up to 1200 Hz. It was found that all but one subject could consistently rank 150- and 200-Hz modulated stimuli by modulation frequency when the carrier rate was more than 800 Hz, but for lower carrier rates the ranking was greatly affected by the harmonic relationship between carrier and modulation frequency. Pitch matching experiments showed that the subjects generally considered the modulated stimuli to be equal in pitch to unmodulated stimuli with rates the same as, or somewhat higher than, the modulation frequency. The results showed that the "pitch" of pulsatile electrical stimulation resulting from periodicities in the time structure of the electrical stimulus has similarities to the "pitch" observed for temporal patterns in acoustic stimulation such as amplitude-modulated noise. There were some differences, however, which may be attributable at least in part to the physiological response differences for electric and acoustic stimulation.

Adult↗

Speech processing for multichannel cochlear implants: variations of the Spectral Maxima Sound Processor strategy.

The Spectral Maxima Sound Processor (SMSP) incorporates a bank of 16 band-pass filters which are assigned to 16 intracochlear electrodes. In each stimulation period 6 electrodes are activated, based on the outputs of the filters with the largest amplitudes. The SMSP has previously been compared with the present MSP(MULTIPEAK) processor and found to improve speech comprehension results. The SMSP speech processing scheme has recently been implemented successfully in a new speech processor, also developed at the University of Melbourne, which utilises digital signal processing techniques. The programming flexibility of this processor has facilitated the investigation of variations of the SMSP strategy which might provide further enhancement of speech perception. Three variations have been investigated: firstly, increasing the constant pulse rate from the usual 250 Hz to 400 Hz; secondly, changing the number of electrodes selected in each stimulation period from 6 to numbers between 4 and 8; thirdly, sharpening the spectral peaks prior to selection of the active electrodes. The results of these studies showed that all three variations had minimal effect on speech perception in quiet, but that increasing the number of electrodes selected for stimulation to 8, or increasing the rate of stimulation, was advantageous for some subjects when listening in background noise.

Acoustic Stimulation↗

Perceptual performance of subjects with cochlear implants using the Spectral Maxima Sound Processor (SMSP) and the Mini Speech Processor (MSP).

A portable sound processor has been developed at the University of Melbourne for use with the 22-electrode cochlear implant manufactured by Cochlear Pty Limited. In this report, the performance of the Spectral Maxima Sound Processor (SMSP) is compared with the Mini Speech Processor (MSP) presently used clinically with this implant. Results of tests with 5 subjects demonstrate that the performance of the SMSP significantly exceeds that of the MSP for recognizing vowels and consonants in closed-set confusion studies and open-set monosyllabic word tests, although recognition of speaker identity and intonation patterns is similar for both processors. Information transmission analysis of phoneme features confirms that most features, such as vowel format frequencies and consonant manner and place of articulation, are better conveyed with the SMSP. Possible reasons for its improved performance are discussed.

Adult↗

A new portable sound processor for the University of Melbourne/Nucleus Limited multielectrode cochlear implant.

A new processor, called the spectral maxima sound processor (SMSP), has been developed for the University of Melbourne/Nucleus Limited multielectrode cochlear implant. The SMSP analyses sound signals by means of a bandpass filterbank having 16 channels which are allocated tonotopically to the implanted electrodes. Every 4 ms, typically, the six channels with the largest amplitudes are selected, and six corresponding electrodes are activated. In an ongoing study the performance of the SMSP is being compared with that of the Mini Speech Processor (MSP). Some results of speech perception tests from the first two SMSP users are presented, in which scores for the recognition of vowels, consonants, and words all showed significant increases over the corresponding MSP scores.

Cochlear Implants↗

A comparison of speech perception of cochlear implantees using the Spectral Maxima Sound Processor (SMSP) and the MSP (MULTIPEAK) processor.

The Spectral Maxima Sound Processor (SMSP) is a portable speech processor which has recently been developed at the University of Melbourne for use with multiple-electrode cochlear implants. In this processor, the six largest outputs (maxima) of 16 bandpass filters are used to stimulate the cochlea on a place basis at a constant rate. This speech processing strategy has been compared with the MSP(MULTIPEAK) strategy, in which four electrodes are selected for stimulation in every glottal pulse period. The study was undertaken on four postlinguistically deaf adults. The results show that, for this group of subjects, the performance of the SMSP processor was significantly better than that of the MSP(MULTIPEAK) processor for the recognition of closed-set vowels and consonants, open-set monosyllabic words, and open-set sentences in noise, when using electrical stimulation alone. The SMSP mean scores were: vowels 91.3%, consonants 74.9%, words 57.4%, and sentences in noise 78.7%. The MSP(MULTIPEAK) mean scores were: vowels 76.3%, consonants 59.4%, words 39.9%, and sentences in noise 50.0%.

Adult↗

High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.

VP-16-213, a congener of epipodophyllotoxin, is a useful chemotherapeutic agent especially against small-cell carcinoma of the lung, germ cell carcinoma, and lymphoma. The standard dose of this drug is limited by myelosuppression. Autologous transplantation of cryopreserved bone marrow assures the restoration of hematopoiesis after marrow ablative cytotoxic therapy. By using this technique, VP-16-213 was dose-escalated using a Fibonacci scheme from the previous highest dose administered to humans (1,500 mg/m2) to 2,700 mg/m2 (900 mg/m2 per day for three consecutive days). At 2,700 mg/m2, severe extramedullary toxicity of the mucous membranes was observed in three of three courses. At the next highest dose (2,400 mg/m2), two of 18 courses (11%, p less than 0.01) resulted in severe mucositis, thus defining this dose as the maximally tolerated dose based on extramedullary toxicities. As anticipated, myelotoxicity was severe but based on the kinetics of marrow recovery, VP-16-213 in these doses appeared not to be marrow ablative. Based on responses observed in this study, high-dose VP-16-213 should be explored in phase II studies or used in combination chemotherapy.

Adolescent↗